via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted
communications organization engaged in connecting public companies
to the investment community, is pleased to announce the release of
the latest episode of The Bell2Bell Podcast as part of its
sustained effort to provide specialized content distribution via
widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive
interviews with executives operating in fast-moving industries.
Bell2Bell’s latest podcast features Dr. Faz Chowdhury, Chairman and
CEO of Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology
company developing and commercializing affordable diagnostic and
digital tools for chronic disease management.
Throughout the interview, Chowdhury provided an introduction to
Nemaura Medical and discussed its business model.
“Nemaura Medical was founded just over a decade back, and, over
that period of time, we’ve been focused on developing a body-worn
sensor designed for both consumer and medical applications in the
diabetes space,” Chowdhury said. “We use the sensor to look at
insight you otherwise could not gauge just by using existing
technologies – taking a drop of blood and putting it on a strip,
for example. … It has taken us a good part of the 10 years to
develop the technical aspects of the product, get the clinical
studies done and get regulatory approvals in Europe. Now, we are
already commercializing product in the U.K., and we are looking at
launching in other places in Europe and then into the U.S.”
“If you look at the market, there are something like half a
billion people around the world with diabetes. For the U.K. market,
we have around 4 million people [with diabetes]; in the U.S., you
have about 30 million people,” he continued. “Our focus at the
moment has been entirely on the U.K. market, because the product is
approved in Europe. We’ve been working with our licensee to supply
sensors. Their first order was for a couple hundred thousand
sensors and a few thousand devices, with rolling forecasts of up to
another couple million sensors over the coming two years. However,
in the U.K., that doesn’t include a second route to market.”
“There are a number of medications that are supplied to people
with type II diabetes with a view to helping them improve control
over their sugar levels. The issue is that … if they’ve got no way
of really measuring the benefit, you’ve got no idea of what the
outcome really is,” Chowdhury added. “In this case, we have a
license agreement whereby our licensee will actually be supplying
the sensors free of charge with those medicines – and those
medicines are reimbursed. … There are over 2 million prescriptions
written every month in the U.K. and Germany alone. … The number of
devices and sensors and, therefore, the revenue projections are
quite significant. We are expecting to get into that second strand
of commercialization with the combination of the sensor and the
drug by the end of the year.”
Join IBN’s Stuart Smith and Dr. Faz Chowdhury, Chairman and CEO
of Nemaura Medical Inc. (NASDAQ: NMRD), to learn more about the
company’s seasoned management team, as well as its recent
milestones and its goals for the balance of 2022 and beyond.
To hear the episode and subscribe for future podcasts,
visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers and the growing IBN Podcast
Series. For more than 15 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About Nemaura Medical Inc.
Nemaura Medical Inc. is a medical technology company developing
and commercializing non-invasive wearable diagnostic devices. The
company is currently commercializing sugarBEAT® and proBEAT™.
sugarBEAT®, a CE mark-approved Class IIb medical device, is a
non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S.
FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital health care subscription
service in the U.S. as a general wellness product as part of its
BEAT® diabetes program that is currently undergoing pilot
studies.
Additionally, Nemaura has launched a beta trial of Miboko, a
metabolic health and well-being program using a non-invasive
glucose sensor along with an AI mobile application that helps a
user understand how certain foods and lifestyle habits can impact
one’s overall metabolic health and well-being.
For more information, visit the company’s website at
www.NemauraMedical.com.
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 15+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform,
IBN provides: (1) access to a network of wire solutions via
InvestorWire to reach all target markets, industries and
demographics in the most effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3) Press Release
Enhancement to ensure maximum impact; (4) full-scale distribution
to a growing social media audience; (5) a full array of corporate
communications solutions; and (6) total news coverage
solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com.
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website, applicable to all content provided by
IBN wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBN (InvestorBrandNetwork)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024